{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Palmerini E"],"funding":["Daiichi Sankyo, Inc.","NCI NIH HHS"],"pagination":["e425-e435"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10243766"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(6)"],"pubmed_abstract":["Background
The Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry is an international prospective study that -previously described the impact of diffuse-type tenosynovial giant cell tumour (D-TGCT) on patient-reported outcomes (PROs) from a baseline snapshot. This analysis describes the impact of D-TGCT at 2-year follow-up based on treatment strategies.Material and methods
TOPP was conducted at 12 sites (EU: 10; US: 2). Captured PRO measurements assessed at baseline, 1-year, and 2-year follow-ups were Brief Pain Inventory (BPI), Pain Interference, BPI Pain Severity, Worst Pain, EQ-5D-5L, Worst Stiffness, and -Patient-Reported Outcomes Measurement Information System. Treatment interventions were no current/planned treatment (Off-Treatment) and syste"],"journal":["The oncologist"],"pubmed_title":["Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies."],"pmcid":["PMC10243766"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Schreuder H","van de Sande M","Healey JH","Gelderblom H","Palmerini E","Leithner A","Mercier F","Laeis P","Lopez-Bastida J","Ye X","Bauer S","Martin-Broto J","Bernthal NM","Gouin F","Staals EL"],"additional_accession":[]},"is_claimable":false,"name":"Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.","description":"Background
The Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry is an international prospective study that -previously described the impact of diffuse-type tenosynovial giant cell tumour (D-TGCT) on patient-reported outcomes (PROs) from a baseline snapshot. This analysis describes the impact of D-TGCT at 2-year follow-up based on treatment strategies.Material and methods
TOPP was conducted at 12 sites (EU: 10; US: 2). Captured PRO measurements assessed at baseline, 1-year, and 2-year follow-ups were Brief Pain Inventory (BPI), Pain Interference, BPI Pain Severity, Worst Pain, EQ-5D-5L, Worst Stiffness, and -Patient-Reported Outcomes Measurement Information System. Treatment interventions were no current/planned treatment (Off-Treatment) and syste","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-07-14T21:14:55.443Z","creation":"2025-04-04T14:40:00.75Z"},"accession":"S-EPMC10243766","cross_references":{"pubmed":["36869793"],"doi":["10.1093/oncolo/oyad011"]}}